Carmat Gets FDA Conditional Approval To Start Second EFS Study Cohort In The US
April 14 (Reuters) - Carmat SA ALCAR.PA:
RECRUITMENT FOR SECOND COHORT EXPECTED TO BEGIN IN H2 2025
CARMAT: RECRUITMENT OF SECOND COHORT EXPECTED TO BEGIN IN H2 2025
CARMAT RECEIVES FDA CONDITIONAL APPROVAL TO INITIATE THE SECOND COHORT OF THE EFS STUDY IN THE UNITED STATES
TO INITIATE IMPLANTS IN SECOND HALF OF 2025
EFS STUDY INVOLVES 10 PATIENTS, PRIMARY ENDPOINT IS 6-MONTH SURVIVAL
TO SEEK FDA APPROVAL FOR LATEST VERSION OF AESON
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Vanguard ETF Could Beat the S&P 500 Again in 2026 —— Why Investors Are Paying Attention

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Tradingkey







